文献速递类风湿关节炎脊柱关节炎

Janus激酶抑制剂与肿瘤坏死因子抑制剂在类风湿关节炎、银屑病关节炎和脊柱关节炎中安全性良好且药物留存率相似:来自BIOBADASER登记的真实世界数据

Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry.
PubMed 文献 · Ann Rheum Dis · 2024-08-27

基于BIOBADASER 3.0登记2015至2023年6826例接受JAKi或TNFi治疗的患者,比较安全性及药物留存。JAKi组全因感染和胃肠道事件IRR在RA患者中更高,但JAKi停药概率更低(HR=0.85),两组1、2、3年留存率相似。

要点

  • RA患者中JAKi组全因感染和胃肠道事件IRR高于TNFi组。
  • JAKi停药概率低于TNFi(HR=0.85;95%CI 0.78-0.92)。
  • 1、2、3年留存率TNFi为69%、55%、45%,JAKi为68%、54%、45%。

核心结论

  • RA患者中感染、带状疱疹和胃肠道不良事件在JAKi治疗时趋于更频繁,但接受JAKi治疗的患者预后较差。
  • TNFi与JAKi的留存率相似,尽管与停药相关的因素因诊断组而异。

研究设计与样本

  • 分析BIOBADASER 3.0登记中2015至2023年接受JAKi或TNFi治疗的患者数据,估计不良事件发生率比(IRR)和药物留存。
  • 共纳入6826例患者,52%为RA,25%为银屑病关节炎,23%为中轴型SpA;86%接受TNFi治疗。

主要发现

  • TNFi平均治疗时长2.2±2.0年,JAKi为1.8±1.5年。
  • JAKi更多用于年龄更大、病程更长、合并症更多、治疗线数更晚的患者,且更常作为单药治疗。
  • RA患者中JAKi组全因感染和胃肠道事件的IRR更高。
  • 1、2、3年药物留存率TNFi为69%、55%、45%,JAKi为68%、54%、45%。
  • 多变量回归模型显示JAKi停药概率更低(HR=0.85;95%CI 0.78-0.92),联用传统合成改善病情抗风湿药停药概率更低(HR=0.90;95%CI 0.84-0.96)。

关键数值与推荐

  • JAKi停药HR=0.85(95%CI 0.78-0.92)。
  • 联用传统合成改善病情抗风湿药停药HR=0.90(95%CI 0.84-0.96)。
  • 糖皮质激素、合并症、更高疾病活动度和更晚治疗线数增加停药风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare the safety of Janus kinase inhibitors (JAKi) with that of tumour necrosis factor inhibitors (TNFi) and determine drug persistence among patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA). METHODS: We analysed data from patients included in BIOBADASER 3.0 and treated with JAKi or TNFi from 2015 to 2023 and estimated the incidence rate ratio (IRR) of adverse events and persistence. RESULTS: A total of 6826 patients were included. Of these, 52% had RA, 25% psoriatic arthritis and 23% axial SpA. Treatment was with TNFi in 86%. The mean duration of treatment was 2.2±2.0 years with TNFi versus 1.8±1.5 with JAKi. JAKis were prescribed in older patients with longer term disease, greater comorbidity and later treatment lines and more frequently as monotherapy. The IRR of all infections and gastrointestinal events was higher among patients with RA treated with JAKi. Drug persistence at 1, 2 and 3 years was 69%, 55% and 45% for TNFi and 68%, 54% and 45% for JAKi. Multivariate regression models showed a lower probability of discontinuation for JAKi (HR=0.85; 95% CI 0.78-0.92) and concomitant conventional synthetic disease-modifying antirheumatic drugs (HR=0.90; 95% CI 0.84-0.96). The risk of discontinuation increased with glucocorticoids, comorbidities, greater disease activity and later treatment lines. CONCLUSIONS: Infections, herpes zoster and gastrointestinal adverse events in patients with RA tended to be more frequent with JAKi. However, prognosis was poor in patients receiving JAKi. Persistence was similar for TNFi and JAKi, although factors associated with discontinuation differed by diagnostic group.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Hernández-Cruz B, Otero-Varela L, Freire-González M, et al. Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry. Ann Rheum Dis. 2024. PMID: 38594056. doi:10.1136/ard-2023-225271

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。